To embed, copy and paste the code into your website or blog:
Virginia has joined California as the second state to enact a comprehensive data privacy law. On March 2, 2021, Virginia Governor Ralph Northam signed the Virginia Consumer Data Protection Act (VCDPA) into law. The VCDPA does not go into effect until January 1, 2023, but the broad privacy mandate will have an immediate impact on compliance efforts for many Virginia businesses.
The law includes elements similar to those found in the California Consumer Privacy Act (CCPA) and the newly enacted California Privacy Rights Act (CPRA), such as provisions granting Virginia residents the right to access, correct, delete, know about, and opt out of the sale and processing of their personal information for “targeted advertising” purposes. Similar to the European Union’s privacy analog, the General Data Protection Regulation (GDPR), the VCDPA imposes data security and consumer response obligations on the data “controller” a
New Virginia Law Helps More Families Get Child Care
publicnewsservice.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnewsservice.org Daily Mail and Mail on Sunday newspapers.
Feeling The Green Rush, Virginia Governor Proposes Moving Up Timeline For Legalizing Pot
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
To embed, copy and paste the code into your website or blog:
On March 24, 2021, Virginia Governor Ralph Northam signed HB 2007, adding Virginia to the growing list of states that have enacted drug pricing transparency measures. The new law, which takes effect January 1, 2022, establishes drug price transparency requirements for manufacturers, wholesale distributors, PBMs, and carriers.
The legislation establishes an annual (by April 1) reporting requirement for manufacturers with respect to 1) brand-name drugs and non-biosimilar biologicals with a WAC of $100 or more for a 30-day supply or course of treatment and any increase of 15% or more in WAC over the preceding calendar year; and 2) biosimilars launched with an initial WAC that is not at least 15% less than the WAC of the reference biologic.